Login to Your Account



Clinic Roundup


Tuesday, December 6, 2011
• Spectrum Pharmaceuticals Inc., of Henderson, Nev., said it filed an investigational new drug application for SPI-014 (formerly called Renazorb), a second-generation lanthanum-based nanoparticle phosphate binding agent that has the potential to treat hyperphosphatemia in patients with Stage V chronic kidney disease, or end-stage renal disease. The company anticipates starting Phase I studies as soon as possible after FDA review.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription